Related Experiment Videos

Fate of erythrocyte Cd-metallothionein in mice

Insights

Metallothionein (MT) in red blood cells degrades with the cell's lifespan after cadmium exposure. Cadmium from degraded MT is then stored in the spleen and liver.

Area of Science:

  • Toxicology
  • Biochemistry
  • Cell Biology

Background:

  • Metallothionein (MT) is induced in erythrocytes following cadmium (Cd) exposure.
  • The degradation pathway and fate of erythrocyte-bound Cd-MT are not fully understood.

Purpose of the Study:

  • To investigate the degradation of cadmium-metallothionein (Cd-MT) in mouse erythrocytes.
  • To determine the relationship between Cd-MT decay in erythrocytes and erythrocyte lifespan.
  • To track the in vivo distribution of cadmium released from erythrocyte MT.

Main Methods:

  • In vitro degradation assays using hemolysate and liver homogenate.
  • In vivo studies involving administration of 109CdCl2 and [3H]diisopropylfluorophosphate to mice.
  • Erythrocyte transfusion experiments to track Cd-MT fate in recipient mice.

Main Results:

  • Cd-MT showed limited degradation by hemolysate in vitro compared to liver homogenate.
  • Radioactivity of both 109Cd and 3H decreased similarly in erythrocytes, correlating with erythrocyte lifespan.
  • Transfused erythrocytes containing 109Cd-MT showed decreasing 109Cd levels, with a marked increase in spleen and liver cadmium concentrations.

Conclusions:

  • Erythrocyte metallothionein degrades concurrently with the erythrocyte.
  • Cadmium released from degraded erythrocyte MT is sequestered in the spleen and liver.
  • The spleen and liver act as deposition sites for cadmium during red blood cell catabolism.

Related Concept Videos